PFM Health Sciences’s Alibaba BABA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-70,083
Closed -$13.6M 78
2020
Q1
$13.6M Buy
70,083
+25,672
+58% +$5.36M 1.12% 35
2019
Q4
$9.42M Sell
44,411
-36,793
-45% -$6.9M 0.45% 50
2019
Q3
$13.6M Sell
81,204
-490,172
-86% -$84.2M 0.4% 56
2019
Q2
$96.8M Buy
571,376
+389,164
+214% +$67.2M 1.84% 14
2019
Q1
$33.2M Buy
182,212
+7,928
+5% +$1.33M 0.73% 47
2018
Q4
$23.9M Sell
174,284
-21,996
-11% -$3.25M 0.63% 54
2018
Q3
$32.3M Sell
196,280
-201,506
-51% -$35.7M 0.47% 74
2018
Q2
$73.8M Buy
397,786
+118,285
+42% +$22.5M 1.16% 29
2018
Q1
$51.3M Sell
279,501
-80,919
-22% -$15.2M 1.04% 38
2017
Q4
$62.1M Sell
360,420
-3,921
-1% -$703K 1.47% 27
2017
Q3
$62.9M Sell
364,341
-338,705
-48% -$54.9M 1.24% 29
2017
Q2
$99.1M Sell
703,046
-106,973
-13% -$13.2M 2.67% 6
2017
Q1
$87.3M Buy
+810,019
New +$82.4M 2.19% 11
2016
Q4
Sell
-240,069
Closed -$25.4M 96
2016
Q3
$25.4M Sell
240,069
-90,666
-27% -$8.4M 0.74% 51
2016
Q2
$26.3M Buy
330,735
+170,639
+107% +$13.4M 0.79% 51
2016
Q1
$12.7M Sell
160,096
-891,730
-85% -$62.8M 0.39% 61
2015
Q4
$85.5M Buy
+1,051,826
New +$82.5M 2.6% 12

Other funds holding BABA

PFM Health Sciences's BABA Position: Q2 2020 in Review

PFM Health Sciences sold out of Alibaba (BABA) in Q2 2020, closing a stake of 70,083 shares — an estimated $13.6M sold.

PFM Health Sciences first reported a position in BABA in Q4 2015 and held it in 17 quarters. The position peaked at $99.1M in Q2 2017. 1,772 funds tracked by Wall St. Rank hold BABA as of Q2 2020.

  • PFM Health Sciences reported no remaining Alibaba position as of Q2 2020 after selling out during the quarter.
  • PFM Health Sciences sold 70,083 Alibaba shares in Q2 2020, an estimated $13.6M.
  • PFM Health Sciences first reported a position in Alibaba in Q4 2015 and held it in 17 quarters.
  • PFM Health Sciences's Alibaba position peaked at $99.1M in Q2 2017.
  • 1,772 funds tracked by Wall St. Rank held Alibaba as of Q2 2020.

Based on PFM Health Sciences's 13F filing for Q2 2020, filed 14 Aug 2020.